Stocktoria
Viking Therapeutics, Inc. VKTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-04-29
Chart by TradingView
1/9
Piotroski F — financial health
7.05
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M |
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M |
| Shareholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M |
| Ratios | |||||
| Return on assets | -50.2% | -12.1% | -23.3% | -40.9% | -26.1% |
| Return on equity | -56.3% | -12.5% | -24.7% | -47.4% | -27.2% |
| Current ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Bridgewater Associates, LP | 71,229 | $2.3M |
| Point72 Asset Management, L.P. | 19,000 | $618,260 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.05 (safe)
- Working capital / assets 0.893
- Retained earnings / assets -1.184
- EBIT / assets -0.55
- Equity / liabilities 8.336
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001607678 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.